

Safety Data Sheet

Document no: SDS-SAGE-05-EN

Product:	Quinn's Advantage® Blastocyst Medium	Page 1/8
Date first created: 2000	Version 7	Date revised: 2025.May.01

Section 1 – PRODUCT AND COMPANY IDENTIFICATION

1.1. Product identifier:

Product Name: Quinn's Advantage® Blastocyst Medium
Catalog Number: ART-1029

1.2. Relevant identified uses of the substance or mixture and uses advised against:

This product is intended for embryo culture from Day 3 through to the blastocyst stage. Can also be used for embryo transfer.

1.3. Details of the supplier of the safety data sheet:

Responsible person for the safety data sheet (e-mail): ra@coopersurgical.com

Legal Manufacturer:

CooperSurgical, Inc.
95 Corporate Drive
Trumbull, CT 06611
USA

Contract manufacturers:

COOPER MEDICAL SRL
Edificio N B49, 51 Ave 0
Parque Industrial Zona Franca Coyol
La Garita, Alajuela COSTA RICA 20113
+45 46 79 02 00 (RA – DK)

1.4. Emergency telephone:

(UK)

NHS (England or Wales): 0845 46 47
NHS 24 (Scotland): 08454 24 24 24

(DK)

Poison line +45 82 12 12 12

Section 2 – HAZARD(S) IDENTIFICATION

2.1. Classification of the substance or mixture:

The product is a medical device (IVF) and therefore not covered by the CLP Regulation (EC) No. 1272/2008.

2.2. Label elements:

None.

2.3. Other hazards:

PBT/vPvB: the product contains no substance which is considered PBT/vPvB according to criteria in Annex XIII.

Product contains the aminoglycoside, gentamicin sulfate.

This broad-spectrum antibiotic has been associated with nephrotoxicity and/or ototoxicity when administered i.v. and serum concentrations are maintained at static levels above 10 mcg/mL for extended periods.



Safety Data Sheet

Document no: SDS-SAGE-05-EN

Product:	Quinn's Advantage® Blastocyst Medium	Page 2/8
Date first created: 2000	Version 7	Date revised: 2025.May.01

Section 3 – COMPOSITION / INFORMATION ON INGREDIENTS

3.2. Mixtures:

An aqueous, isotonic, complex mixture of organic and inorganic salts and simple carbohydrates, at neutral pH intended for in vitro mammalian cell culture. Contains 0.010 mg/mL gentamicin and 0.003 mg/mL phenol red as a pH indicator.

Component	CAS / EC no.	Approx. %	Classification
Physiological salts including:		< 1	
Magnesium Sulfate, Heptahydrate	10034-99-8		Not classified
Potassium Chloride	7447-40-7		Not classified
Potassium Phosphate, monobasic	7778-77-0		Not Classified
Sodium citrate, dihydrate	7558-79-4		Not classified
Sodium Chloride (USP)	7647-14-5		Eye Irrit. 2
Sodium Bicarbonate	144-55-8	< 1	Not classified
Gentamicin Sulfate (EP)	1405-41-0	10 µg/ml	Skin Sens. 1, H317 Resp. Sens. 1, H334
Amino Acids including:		< 1	
Glycine	58-40-6		Not classified
L-Arginine monohydrochloride,	1119-34-2		Skin Irrit. 2, H315 Eye Irrit. 2, H319
L-Phenylalanine,	63-91-2		Eye Irrit. 2, H319
Taurine,	107-35-7		Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE H335 (not specified)
L-Cystine 2HCl	30925-07-6		Skin Corr. 1B, H314 Eye Dam. 1, H318
Vitamins incl. Energy substrates:		< 1	
Pyridoxine HCl	58-56-0		Eye Irrit. 2, H319
D-(+)-Glucose (Dextrose)	50-99-7		Not classified

Safety Data Sheet

Document no: SDS-SAGE-05-EN

Product:		Quinn's Advantage® Blastocyst Medium		Page 3/8
Date first created: 2000		Version 7		Date revised: 2025.May.01
Hydrochloric acid, 37% 10N	7647-01-0	< 0,01	Eye Irrit. 2; H319: 10 % ≤ C < 25 % STOT SE 3; H335: C ≥ 10 % Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 %	
Phenol Red Sodium salt	34487-61-1	< 0,01	Skin Irrit. 2 H315 Eye Irrit. 2, H319 STOT SE 3 H335	
Sodium Hydroxide 10N	1310-73-2	< 0,01	Eye Irrit. 2; H319: 0,5% ≤ C < 2% Skin Corr. 1A; H314: C ≥ 5% Skin Corr. 1B; H314: 2% ≤ C < 5% Skin Irrit. 2; H315: 0,5 % ≤ C < 2%	
Milli RX Water		> 90	Not classified	

Section 4 – FIRST-AID MEASURES

4.1. Description of first aid measures:

Inhalation:	Not relevant.
Skin contact:	In case of skin contact, wash immediately and thoroughly with soap and water.
Eye contact:	In case of eye contact, flush with copious quantities of water. Remove contact lenses, if any; In case of serious hypersensitivity reaction, rush for immediate medical attention.
Ingestion:	If swallowed, wash out mouth with water provided the person is conscious. Call a physician.

4.2. Most important symptoms and effects, both acute and delayed:

None known.

4.3. Indication of any immediate medical attention and special treatment needed:

None known.

Safety Data Sheet

Document no: SDS-SAGE-05-EN

Product:	Quinn's Advantage® Blastocyst Medium	Page 4/8
Date first created: 2000	Version 7	Date revised: 2025.May.01

Section 5 – FIRE FIGHTING MEASURES

5.1. Extinguishing media:

Use water, CO₂ or any other media suitable for extinguishing fire.

5.2. Special hazards arising from the substance or mixture:

Non-flammable.

5.3. Advice for firefighters:

Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

Section 6 – ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures:

None required.

6.2. Environmental precautions:

None required.

6.3. Methods and material for containment and cleaning up:

Use absorbent material to mop up spill. Wash area with water.

Further handling of spillage/waste - see section 13.

6.4. Reference to other sections:

See above.

Section 7 – HANDLING AND STORAGE

7.1. Precautions for safe handling:

Use care in handling/storage. Avoid any unnecessary contact with skin, eyes or mucus membranes.

Use aseptic working techniques at all times. Do not mouth pipette. After work wash hands with water and mild soap. Individuals with previous history of allergy to antibiotics and/or asthma, should avoid potential exposure.

7.2. Conditions for safe storage, including any incompatibilities:

Store the product at 2° - 8°C upon receipt. Unused product may be kept refrigerated at 2° - 8°C until the expiration date indicated on the label. Close container tightly after use.

In addition see manufacturer's specifications.

7.3. Specific end use(s):

See section 1.

Section 8 – EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1. Control parameters:

Occupational exposure limits (Manufacturer recommended OEL) - **EH40/2005 Workplace exposure limits:**

	Long-term exposure limit (8-hr TWA ref. period)	Short-term exposure limit (15-minute ref. period)
	ppm / mg.m-3	ppm / mg.m-3
Hydrochloric Acid:	1 / 2	5 / 8
Sodium Hydroxide :	- / -	- / 2

EU Exp. Limit 5 ppm / 7 mg/m3 Ceiling limit.

CooperSurgical - ORIGIO a/s
Lautrupvang 2, 1st floor 2750 Ballerup, Denmark
Web: www.Coopersurgical.com

Safety Data Sheet

Document no: SDS-SAGE-05-EN

Product:	Quinn's Advantage[®] Blastocyst Medium	Page 5/8
Date first created: 2000	Version 7	Date revised: 2025.May.01

DNEL/PNEC: No CSR.

8.2. Exposure controls:

Appropriate engineering controls:	Local exhaust is adequate; mechanical (general) ventilation is recommended.
Environmental exposure controls:	None known.

Personal protective equipment:

Respiratory protection:	None Required
Skin protection:	Disposable medical gloves, such as disposable nitrile gloves.
Eye protection:	Use Safety glasses.
Other Protective Equipment:	Work clothes, including standard precautions for healthcare workers

Section 9 – PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties:

Appearance:	Particle-free, Pink-rose color, clear liquid
Odour/ Odour threshold:	Not available/ Not determined
pH:	Not available/ Not determined
Melting point/freezing point (°C):	Not available/ Not determined
Initial boiling point and boiling range (°C):	Not available/ Not determined
Flash point (°C):	Not available/ Not determined
Evaporation rate:	Not available/ Not determined
Flammability (solid, gas):	Not relevant
Upper/lower flammability or explosive limits (vol-%):	Not relevant
Vapour pressure:	Not available/ Not determined
Specific gravity:	~1.0
Solubility:	Not available/ Not determined
Partition coefficient: n-octanol/water:	Not available/ Not determined
Auto-ignition temperature (°C):	Not relevant
Decomposition temperature (°C):	Not available/ Not determined
Viscosity:	Not available/ Not determined
Explosive properties:	Not relevant

9.2. Other information:

None.

Section 10 – STABILITY AND REACTIVITY

10.1. Reactivity:

None.

10.2. Chemical stability:

Stable.

10.3. Possibility of hazardous reactions:

Will not occur.

CooperSurgical - ORIGIO a/s
Lautrupvang 2, 1st floor 2750 Ballerup, Denmark
Web: www.Coopersurgical.com

SDS-ART-1029, Rev. 07

Safety Data Sheet

Document no: SDS-SAGE-05-EN

Product: Quinn's Advantage® Blastocyst Medium **Page 6/8**

Date first created: 2000

Version 7

Date revised: 2025.May.01

10.4. Conditions to avoid:

Do not expose product to elevated temperatures (above 40 °C) for extended periods of time. Store product at 2–8 °C when not being used. Deterioration of the liquid medium may be recognized by any or all of the following: pH change, precipitate or particulates, cloudy appearance, color change.

10.5. Incompatible materials:

None

10.6. Hazardous decomposition products:

Thermal decomposition of the product will not occur.

Section 11 – TOXICOLOGICAL INFORMATION

11.1. Information on toxicological effects:

No available information. (LD50 not established for the individual components).
Information on likely routes of exposure: Not expected for this product.

Inhalation:	No effects expected.
Skin:	No effects expected.
Eyes:	No effects expected.
Ingestion:	No effects expected.
Chronic effects:	Individuals with previous history of allergy to antibiotics and/or asthma, should avoid potential exposure.

11.2. Information on other hazards

Product contains the aminoglycoside, gentamicin sulfate.
This broad-spectrum antibiotic has been associated with nephrotoxicity and/or ototoxicity when administered i.v. and serum concentrations are maintained at static levels above 10 mcg/mL for extended periods.

Section 12 – ECOLOGICAL INFORMATION

12.1. Toxicity:

No data available.

12.2. Persistence and degradability:

No data available.

12.3. Bioaccumulative potential:

No data available.

12.4. Mobility in soil:

No data available.

12.5. Results of PBT and vPvB assessment:

The substances are not considered PBT/vPvB according to criteria in Annex XIII.

12.6. Endocrine disrupting properties

No data available.

CooperSurgical - ORIGIO a/s
Lautrupvang 2, 1st floor 2750 Ballerup, Denmark
Web: www.Coopersurgical.com

Safety Data Sheet
Document no: SDS-SAGE-05-EN

Product: Quinn's Advantage® Blastocyst Medium **Page 7/8**

Date first created: 2000 **Version** 7 **Date revised:** 2025.May.01

12.7. Other adverse effects:

No ecological information available.

Section 13 – DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods:

Disposal should be in accordance with existing disposal practices employed at your institution for infectious waste. Observe all federal, state, and local environmental regulations for waste disposal.

Disposed of in an approved land fill or incinerate providing local environmental regulations permit.

EWC-code: 18

Section 14 – TRANSPORT INFORMATION

Not classified as dangerous goods for transportation (ADR/RID/IMDG/IATA).

14.1. UN-no.: None.

14.2. UN proper shipping name: None.

14.3. Transport hazard class(es): None.

14.4. Packing group: None.

14.5. Environmental hazards: None.

14.6. Special precautions for user: None.

14.7. Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code:

Not relevant.

Section 15 – REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture:

EU:

Full Quality Assurance No. **CE 82107**

EC Design-Examination Cert. **CE 551319**

Product ART-1026 is remediated and approved under EU MDR: **MDR 768167**

USA:

United States Food and Drug Administration (FDA): 510(k) **K002836**

The product has been evaluated in accordance with CLP Regulation (EC) No 1272/2008 (classification).
The product has been classified as non-hazardous.

15.2. Chemical safety assessment:

Not relevant.

Safety Data Sheet

Document no: SDS-SAGE-05-EN

Product: Quinn's Advantage® Blastocyst Medium **Page 8/8**

Date first created: 2000 **Version** 7 **Date revised:** 2025.May.01

Section 16 – OTHER INFORMATION

Abbreviations:

CSR = Chemical Safety Report
DNEL = Derived No-Effect Level
LD₅₀ = Lethal Dosis 50 %
PBT = Persistent, Bioaccumulative, Toxic
PNEC = Predicted No-Effect Concentration
vPvB = very Persistent, very Bioaccumulative

Training advice:

No special training is required. However, the user should be well instructed according to specific IFU and be familiar with this Safety Data Sheet.

Additional information:

Coopersurgical warrants that its products conform to the information designated herein. The information, data, and recommendations contained herein are believed to be accurate and reported in good faith. The information may not be all inclusive and is to be used only as a guide with caution. Coopersurgical shall not be held liable for any damage resulting from handling, or from contact with the product. We reserve the right to revise this SDS periodically as new information becomes available.

The information contained herein is furnished without warranty of any kind. Users should consider these data only as a supplement to other information gathered by them and must take independent determinations of the suitability and completeness of information from all other sources to assure proper use and disposal of these materials and the safety and health of employees and customers.